DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

ABBV·AbbVie Inc.

$.
-. (-.%)
High
$217.05
Open
$215.92
Market Cap
381.10B
52W High
$244.81
Low
$213.28
P. Close
$215.70
P/E
104.84
52W Low
$180.25
Fwd P/E
13.29
Mean Target
-
Technical Score (1D)
68
BUY
News Sentiment
58
BULLISH
AbbVie has secured positive opinions from the European Medicines Agency's CHMP for two key indications: Boey for glabellar lines and MAVIRET for hepatitis C, signaling potential market expansion in Europe. These developments, alongside upcoming presentations of new oncology data at ASCO and recent strong updates in inflammatory bowel disease therapies, underscore a diversified growth strategy. The company's MAVIRET has received a positive CHMP opinion for treating acute hepatitis C infection in adults and children, with a final European Commission decision anticipated in the third quarter of 2026. Additionally, AbbVie's Allergan Aesthetics received a positive CHMP opinion for Boey (trenibotulinumtoxinE) for the temporary improvement of moderate to severe glabellar lines in adults across 30 EU & EEA markets. In the realm of oncology, AbbVie presented new data at ASCO 2026 highlighting advancements in its pipeline, particularly focusing on novel antibody-drug conjugate (ADC) and T-cell engager platforms for solid tumors and blood cancers. Furthermore, AbbVie presented new real-world and clinical trial data for its IBD therapies, Skyrizi and Rinvoq, at the 2026 Digestive Disease Week Annual Meeting, reinforcing their potential in the inflammatory bowel disease market. These developments come as AbbVie is recognized as a top low-risk stock for 2026, noted for its perceived stability and consistent return potential. As a Dividend King with a 53-year streak of dividend increases, AbbVie is highlighted as a stable dividend growth stock, offering a reliable income stream amidst market uncertainty. Institutional investors, including Mizuho Markets Americas LLC, have also increased their holdings in AbbVie, reflecting confidence in the company's trajectory. Investors will be watching for final European Commission decisions on MAVIRET and Boey, as well as further updates from the oncology pipeline presentations.
Earnings Summary
AbbVie is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines across various therapeutic areas, including immunology, oncology, neuroscience, and eye care. Operating within the broader Healthcare sector, specifically the Drug Manufacturers - General industry, AbbVie focuses on developing treatments for significant unmet medical needs. In its most recent reported quarters, AbbVie demonstrated a mixed performance. For Q1 2026, the company reported actual EPS of $2.65 against an estimate of $3.74, and actual revenue of $15.002 billion against an estimate of $16.804 billion, indicating a miss on both metrics. This followed a Q4 2025 where actual EPS was $2.71, slightly beating the estimate of $2.7053, but actual revenue of $16.618 billion missed the estimate of $16.7489 billion. Looking at the prior two quarters, Q3 2025 saw actual EPS of $1.86 beat the estimate of $1.78451, with revenue not provided, and Q2 2025 reported actual EPS of $2.97 against an estimate of $2.90783, also a beat, with revenue at $15.423 billion. This pattern suggests a recent deceleration in EPS performance, particularly in Q1 2026, following a period of beats in Q2 and Q3 2025. Historically, AbbVie has shown a trajectory of growth, though specific year-over-year comparisons are not directly calculable from the provided data points. The company has a history of beating analyst estimates, particularly in EPS, as seen in Q2 and Q3 2025, but recent quarters have shown a more challenging beat/miss pattern, with a notable EPS miss in Q1 2026. Recent news highlights positive analyst sentiment, with Piper Sandler maintaining an Overweight rating and raising its price target, and positive commentary from Jim Cramer. AbbVie executives presented at the Bank of America Global Healthcare Conference, discussing the underpenetrated obesity market and potential strategic moves. Furthermore, new immunology data for SKYRIZI® and RINVOQ® has led to an upgraded 2026 earnings outlook and an FDA submission for Crohn's disease, alongside a development milestone with Xilio Therapeutics. For the upcoming periods, investors will be watching for AbbVie's strategic actions in the obesity market and continued progress on its pipeline advancements, particularly the impact of new drug submissions and the company's ability to translate positive clinical data into sustained financial performance, especially in light of the recent EPS miss in Q1 2026.

EPS

EstBeatMiss
$1.49$2.13$2.78$3.42$4.06Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.77 - -
Q1'26$3.74$2.65-29.2%
Q4'25$2.71$2.71+0.2%
Q3'25$1.78$1.86+4.2%
Q2'25$2.91$2.97+2.1%
Q1'25$2.40$2.46+2.6%

Revenue

EstBeatMiss
$12.8B$14.0B$15.2B$16.4B$17.7BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$17.1B - -
Q1'26$16.8B$15.0B-10.7%
Q4'25$16.7B$16.6B-0.8%
Q3'25 - $15.8B -
Q2'25 - $15.4B -
Q1'25 - $13.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABBV Stock Snapshot

ABBV is currently trading at $214.07, giving AbbVie Inc. a market cap of 381.10B and a P/E ratio of 104.8. Today's range spans $213.28–$217.05, with shares opening at $215.92 and moving down $1.63 (0.8%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 58/100.

Over the past year ABBV has traded between $180.25 and $244.81 - the current price is +18.8% off the 52-week low and -12.6% from the high.

If you're looking for bullish momentum in Healthcare, ABBV is putting up the numbers: 68/100 technical score, BUY signal, neutral sentiment at 58/100. Price: $214.07 (in the middle of its 52-week range). (P/E: 104.8) The 381.10B market cap keeps it in play for institutional position sizes, and the $180.25–$244.81 annual range shows this stock can make real moves when it gets directional conviction behind it.

The combination of a BUY signal (68/100) and neutral news sentiment (58/100) puts ABBV on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 381.10B in Healthcare market cap without immediately moving the stock. At $214.07 (in the middle of its 52-week range in the $180.25–$244.81 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…